RadioMedix

About RadioMedix

RadioMedix is a clinical stage biotechnology company focused on radiopharmaceuticals for oncology, developing and commercializing targeted alpha and beta therapies as well as next-generation diagnostic imaging agents. Based in Houston, Texas, the company spans early-stage R&D to commercial-scale GMP manufacturing and works with isotopes such as Ac-225, Lu-177, Pb-212, Pb-203, and Ga-68 to treat and diagnose cancers. From concept to clinic, RadioMedix emphasizes scientific rigor, speed, and partnerships to advance its pipeline and CDMO collaborations while aiming to disrupt the standard of care in cancer diagnosis and treatment.